{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:48:39Z","timestamp":1765079319953},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.radonc.2016.12.030","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T15:52:06Z","timestamp":1484236326000},"page":"464-469","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial"],"prefix":"10.1016","volume":"122","author":[{"given":"Vivek","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey J.","family":"Lazenby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijeet R.","family":"Bhirud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan P.","family":"Ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrakanth","family":"Are","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron R.","family":"Sasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2016.12.030_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2016.12.030_b0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COC.0000000000000278","article-title":"Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications","volume":"39","author":"Verma","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0360-3016(97)00101-6","article-title":"Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck","volume":"38","author":"Brizel","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ijrobp.2003.11.004","article-title":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer","volume":"58","author":"Koong","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijrobp.2005.07.002","article-title":"Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer","volume":"63","author":"Koong","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0035","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","author":"Schellenberg","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cncr.24059","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","author":"Chang","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2016.12.030_b0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s11605-010-1323-7","article-title":"Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma: results of first 85 patients","volume":"14","author":"Didolkar","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.radonc.2016.12.030_b0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2010.05.006","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-8-44","article-title":"Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety","volume":"8","author":"Gurka","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0060","first-page":"238","article-title":"Clinicopathologic study of dextran sulfate sodium experimental murine colitis","volume":"69","author":"Cooper","year":"1993","journal-title":"Lab Invest"},{"key":"10.1016\/j.radonc.2016.12.030_b0065","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2000.01924.x","article-title":"The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications","volume":"95","author":"Carpenter","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.radonc.2016.12.030_b0070","series-title":"In vivo models of inflammation","year":"2006"},{"key":"10.1016\/j.radonc.2016.12.030_b0075","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","article-title":"HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo","volume":"65","author":"Gupta","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2016.12.030_b0080","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2007.15.2355","article-title":"Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer","volume":"26","author":"Brunner","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0085","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines for Pancreatic Cancer. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/pancreatic.pdf [accessed July 31, 2016]."},{"key":"10.1016\/j.radonc.2016.12.030_b0090","unstructured":"Clinical Trials, US National Institutes of Health. Clinical Trial NCT01068327. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01068327 [accessed December 23, 2016]."},{"key":"10.1016\/j.radonc.2016.12.030_b0095","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0100","unstructured":"Radiation Therapy Oncology Group. Upper abdominal normal organ contouring consensus guidelines. https:\/\/www.rtog.org\/CoreLab\/ContouringAtlases\/UpperAbdominalNormalOrganContouringConsensusGuidelines.aspx [accessed August 8, 2015]."},{"key":"10.1016\/j.radonc.2016.12.030_b0105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0110","unstructured":"Radiation Therapy Oncology Group. RTOG 0631 Protocol Information. https:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=0631 [accessed August 8, 2015]."},{"key":"10.1016\/j.radonc.2016.12.030_b0115","series-title":"Rosai and Ackerman's surgical pathology","volume":"Vol. 1","author":"Rosai","year":"2011"},{"key":"10.1016\/j.radonc.2016.12.030_b0120","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.09.075","article-title":"A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer","volume":"78","author":"Murphy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0125","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ijrobp.2011.09.022","article-title":"Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma","volume":"83","author":"Huang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijrobp.2012.06.005","article-title":"Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies","volume":"84","author":"Bae","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2012.09.035","article-title":"Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer","volume":"85","author":"Kelly","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0140","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ijrobp.2012.07.2366","article-title":"Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer","volume":"85","author":"Taniguchi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.12.030_b0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13014-015-0489-2","article-title":"Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas","volume":"10","author":"Elhammali","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.15.2355","article-title":"Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer","volume":"26","author":"Brunner","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","article-title":"ARCII: a phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer","volume":"119","author":"Wilson","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.meddos.2013.02.003","article-title":"Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis","volume":"38","author":"Kumar","year":"2013","journal-title":"Med Dosim"},{"key":"10.1016\/j.radonc.2016.12.030_b0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.meddos.2015.04.002","article-title":"Dosimetric benefit of adaptive re-planning in pancreatic cancer stereotactic body radiotherapy","volume":"40","author":"Li","year":"2015","journal-title":"Med Dosim"},{"key":"10.1016\/j.radonc.2016.12.030_b0170","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/0284186X.2012.762997","article-title":"Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity","volume":"52","author":"Nichols","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b9000","doi-asserted-by":"crossref","first-page":"644","DOI":"10.21037\/jgo.2016.05.06","article-title":"Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review","volume":"7","author":"Verma","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2016.12.030_b0175","doi-asserted-by":"crossref","first-page":"081711","DOI":"10.1118\/1.4887797","article-title":"A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas","volume":"41","author":"Thompson","year":"2014","journal-title":"Med Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016344826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016344826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T12:56:07Z","timestamp":1568724967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814016344826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0167814016344826"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2016.12.030","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2016.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}